Apitope has established a robust process for identifying tolerogenic peptides. The platform utilizes a number of decision making assay systems that are run internally or with external service providers.
Our simple and quick in vitro screening method first identifies peptides that do not require processing by antigen presenting cells but are capable of binding to the MHC II molecules on the surface of these cells. The patented method significantly reduces the number of possible T cell epitopes that require evaluation during cumbersome and expensive in vivo tests.
In the following phases of our process, human T cell reagents are generated, an important component in the design of Apitopes®, which are used to identify T cell epitopes. The human T cell reagents are specific for naturally processed antigens. Apitopes® are selected to have the potential to stimulate these cells when presented to them by antigen presenting cells.
Subsequent in vivo data on the newly discovered Apitopes® assesses the capacity of the Apitopes® to induce tolerance to the auto-antigen from which they were developed. Eventually, these Apitopes® are intended to induce a Treg response when administered in soluble form to a human carrying the appropriate MHC II receptor.
When an Apitope® has been characterized in the in vitro and in vivo assays and passes our selection criteria at each stage, it is designated as a product candidate and moved into the pre-clinical development phase.
Apitope’s patented, leading edge, high speed discovery platform enables it to identify and design peptide-based therapeutics using a fast, reliable and cost-efficient process. This proprietary Apitope approach to epitope selection equally ensures that the peptides taken into clinical evaluation are likely to be safe, well tolerated, and have a higher probability of efficacy.